SUSTOL bike rider

Patients with CINV face a rough road ahead;

Choose full 5-day protection to smooth the journey

SUSTOL—the first and only 5-HT3 RA engineered with novel polymer technology that enables the extended release of granisetron for proven 5-day CINV protection.1-7

SUSTOL bike rider

SUSTOL—the first and only 5-HT3 RA engineered with novel polymer technology that enables the extended release of granisetron for proven 5-day CINV protection.1-7

5-HT3 RA=5-hydroxytryptamine receptor antagonist; CINV=chemotherapy-induced nausea and vomiting.

References:

  1. SUSTOL [prescribing information]. Heron Therapeutics, Inc., 2017.
  2. Aloxi [prescribing information]. Helsinn Therapeutics (U.S.), Inc., 2020.
  3. Zofran [prescribing information]. GlaxoSmithKline. 2017.
  4. Kytril [prescribing information]. Genentech, Inc., 2011.
  5. Sancuso [prescribing information]. Kyowa Kirin, Inc., 2020.
  6. Anzemet [prescribing information]. Validus Pharmaceuticals LLC, 2016.
  7. Ottoboni et al. J Exp Pharmacol. 2014.